Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Genetic toxicity in vitro

Description of key information

The substance is not expected to be mutagenic in the Ames test based on read-across to the closely related analog substance Sevoflurane which is used as a surgical anesthetic and based on the fact that there were no structural alerts identified for the substance in a Structural Activity Relationships (SAR) assessment of mutagenicity using the software "In vitro mutagenicity (Ames test) alerts by ISS" available in Toxtree (Estimation of Toxic Hazard - A Decision Tree Approach) v3.1.0-1851-1525442531402.

Link to relevant study records

Referenceopen allclose all

Endpoint:
in vitro gene mutation study in bacteria
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
Not Reported
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
Deviations:
yes
Remarks:
Only strains TA1535 and TA100 tested
Principles of method if other than guideline:
Bacteria were exposed to using a direct plate method, using sealed containers, and by exposure to the vapor. Each test consisted of 6 replicates.
GLP compliance:
no
Type of assay:
bacterial reverse mutation assay
Specific details on test material used for the study:
Reported as: Sevoflurane; CH2F-O-CH(CF3)2
Species / strain / cell type:
S. typhimurium TA 1535
Species / strain / cell type:
S. typhimurium TA 100
Metabolic activation:
with and without
Metabolic activation system:
Rat Liver (S9)
Test concentrations with justification for top dose:
Vapor: 0.1%, 1%, 2%, 10%, 20%, and 30% by volume for 8 hours.
Direct Plate: 1, 10, and 30 ul/plate.
Vehicle / solvent:
Vapor testing: Air was the vehicle.
Direct Plate: None
Untreated negative controls:
no
Negative solvent / vehicle controls:
no
True negative controls:
no
Positive controls:
yes
Positive control substance:
other: Vinylidene Chloride (3%)
Details on test system and experimental conditions:
Vapor Testing: Bacteria on petri plates were exposed to test anesthetic vapor for 8 hours in desiccators.
Direct Plate: Liquid anesthetic was added to soft agar and bacteria, and the mixture was spread on histidine-deficient culture medium.
Rationale for test conditions:
Not Reported.
Evaluation criteria:
Number of revertants per plate.
Statistics:
Methods Not Reported.
Key result
Species / strain:
S. typhimurium TA 1535
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 100
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
valid

Vapor Test w/S9 Activation: Number of Revertants per Plate ( ±SD)

Strain

Control Air

Vapor Percent (v/v) (Desiccator)

0.1

1

2

10

20

30

TA1535

23 ±3

27 ± 3

26 ± 7

20 ± 2

23 ± 3

16 ± 1

15 ± 2

TA100

128 ±7

141 ± 9

145 ± 11

124 ± 3

124 ± 23

130 ± 33

150 ± 12

Direct Plate w/S9 Activation: Number of Revertants per Plate ( ±SD)

Strain

Control Air

µl/Plate (Direct Plate)

Positive Control

1

10

30

TA1535

23+/- 3

15 ± 2

13 ± 4

11 ± 3

69 ± 5

TA100

128+/-7

100 ± 12

121 ± 15

100 ± 10

415 ± 25

Conclusions:
The read-across substance, Sevoflurane, was not mutagenic in the Ames test when bacterial strains TA1535 or TA100 were exposed with or without metabolic activation to vapor or when exposed directly to the liquid.
Executive summary:

In a non-GLP study conducted in a manor similar to OECD 471 (Bacterial Reverse Mutation Assay) using bacterial strains TA1535 and TA100 only, the vapor and liquid of the test substance (Sevoflurane) was not mutagenic with or without metabolic activation.

Endpoint:
in vitro gene mutation study in bacteria
Type of information:
(Q)SAR
Adequacy of study:
weight of evidence
Study period:
18 May 2019
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
results derived from a valid (Q)SAR model and falling into its applicability domain, with adequate and reliable documentation / justification
Justification for type of information:
1. SOFTWARE : Toxtree (Estimation of Toxic Hazard - A Decision Tree Approach)

2. MODEL (incl. version number) : In vitro mutagenicity (Ames test) alerts by ISS available in Toxtree (Estimation of Toxic Hazard - A Decision Tree Approach) v3.1.0-1851-1525442531402

3. SMILES OR OTHER IDENTIFIERS USED AS INPUT FOR THE MODEL : COC(C(F)(F)F)C(F)(F)F

4. SCIENTIFIC VALIDITY OF THE (Q)SAR MODEL: The model was developed by Istituto Superiore di Sanita for the EC Joint Research Centre, Computational Toxicology and IdeaConsult Ltd. Sofia, Bulgaria. The basis of the model are explained in detail in Benigni, R. & Bossa, C. (2011). Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem. Revs. 111, 2507-2536. and Benigni, R., Bossa C., Tcheremenskaia O. (2013) In vitro cell transformation assays for an integrated, alternative assessment of carcinogenicity: a data-based analysis. Mutagenesis 2013;28(1):107-16. This model is included in the OECD QSAR Toolbox.

5. APPLICABILITY DOMAIN : The model assesses the chemical's structure and identifies any fragraments or functional groups that have been associated with mutagenicity in the Ames assay. Since this substance contains no unusual elements or functional groups, only C, CH, CH3, O, and F, the substance can be presumed to fit within the models domain.

6. ADEQUACY OF THE RESULT: The SAR model found no structural alerts for mutagenicity in the Ames assay. This result is as expected and is supported by measured data on a similar substance, Sevoflurane, which was negative in the Ames assay with and without metabolic activation.
Qualifier:
no guideline required
Principles of method if other than guideline:
Accepted SAR Model Toxtree Module: In vitro mutagenicity (Ames test) alerts by ISS available in Toxtree (Estimation of Toxic Hazard - A Decision Tree Approach) v3.1.0-1851-1525442531402.
GLP compliance:
no
Type of assay:
bacterial reverse mutation assay
Specific details on test material used for the study:
SMILES Used: COC(C(F)(F)F)C(F)(F)F
Key result
Species / strain:
other: All Common Strains used in Ames Assay
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
not determined
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
not applicable
Remarks on result:
no mutagenic potential (based on QSAR/QSPR prediction)
Conclusions:
The substance does not contain any fragrments or functional groups commonly associated with mutagenicity in the Ames Assay.
Executive summary:

In a Structural Activity Relationships (SAR) assessment of mutagenicity using the software "In vitro mutagenicity (Ames test) alerts by ISS" available in Toxtree (Estimation of Toxic Hazard - A Decision Tree Approach) v3.1.0-1851-1525442531402, there were no structural alerts identified for the substance. It can therefore be concluded that the substance is unlikely to be mutagenic in the Ames Assay. This result is supported by measured data on a similar substance, Sevoflurane, which was negative in the Ames assay with and without metabolic activation.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (negative)

Genetic toxicity in vivo

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

The available data does not support the classification of the substance as mutagenic.